

[ABSTRACT]

The present disclosure relates to a tartrate salt of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, a crystalline form thereof and a method for
5 preparation thereof. The tartrate salt and crystalline form have low hygroscopicity compared to the free base and is improved in stability and solubility, thereby being suitable for pharmaceutical use.

In addition, the method for preparing the tartrate salt and crystalline form according to the present disclosure has the advantage that mass production is
10 made possible and the safety of the preparation process is improved by using safer materials than the reactants used in conventional preparation methods.